Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

WCLC 2021: Epidemiology of MET Exon 14 mutations

Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht...

WCLC 2021: Epidemiology of MET Exon 14 mutations ( Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinger )

OncoAlert and ecancer weekly round up for October 11th - October 16, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for October 11th - October 16, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

ESMO 2021: Latest in EGFR mutated advanced NSCLC

Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera

ESMO 2021: Latest in EGFR mutated advanced NSCLC ( Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera )

First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and...

Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA

First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA ( Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA )

ESMO 2021: PARPi data and their role in mono/combination therapies

Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong

ESMO 2021: PARPi data and their role in mono/combination therapies ( Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong )

ESMO 2021: Updates in hormone-sensitive prostate cancer

Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena...

ESMO 2021: Updates in hormone-sensitive prostate cancer ( Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena Castro )

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant...

Dr Pascale Tomasini and Dr Catherine Shu

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC ( Dr Pascale Tomasini and Dr Catherine Shu )

ESMO 2021: Breast cancer roundup

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ESMO 2021: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally...

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )

Drug combination shows promise in treatment-resistant advanced ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Drug combination shows promise in treatment-resistant advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal...

Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer ( Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA )

More from ecancer